Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have identified that injection frequency and taking anti-retroviral therapy for HIV are risk factors for nonfatal drug overdoses among Russians who are HIV positive and inject drugs. Alexander Walley, MD, MSc, an attending physician in general internal medicine at BMC and an assistant professor of medicine at BUSM, is the study's lead author.

Published in the journal AIDS Care, the study was done in collaboration with the Pavlov State Medical University in Russia.

"Non-fatal overdose among HIV-infected Russians who inject drugs is common, however our study is the first to identify risk factors associated with those cases," said Walley.

The researchers analyzed baseline data of 294 participants with 30-day injection drug use who were taking part in an HIV secondary prevention trial for individuals who self-reported "heavy" alcohol use and risky sexual behavior in the past six months.

More than three quarters of the participants, 76 percent, reported a lifetime history of a non-fatal overdose while 16 percent reported a non-fatal overdose in the previous three months. The data showed that the previous month's injection history and anti-retroviral therapy at the time the participants were interviewed were associated with a non-fatal overdose within the previous three months.

"Our study data demonstrates that these individuals could benefit from overdose prevention efforts," added Walley.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus